胆汁淤积的生物标志物研究进展
蔡晓波, 王建香, 陆伦根 . 胆汁淤积的生物标志物研究进展[J]. 内科理论与实践, 2022 , 17(01) : 11 -14 . DOI: 10.16138/j.1673-6087.2022.01.003
| [1] | Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease[J]. Gut, 2022, 71(1): 194-209. |
| [2] | 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12): 1989-1999. |
| [3] | Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics[J]. Gut, 2016, 65(11): 1895-1905. |
| [4] | Kalas MA, Chavez L, Leon M, et al. Abnormal liver enzymes: a review for clinicians[J]. World J Hepatol, 2021, 13(11): 1688-1698. |
| [5] | 曹旬旬, 高月求, 张文宏, 等. 基于上海市住院慢性肝病患者胆汁淤积患病率的调查研究[J]. 中华肝脏病杂志, 2015, 23(8): 569-573. |
| [6] | Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis-a comprehensive review[J]. J Hepatol, 2017, 67(6): 1298-1323. |
| [7] | Appanna G, Kallis Y. An update on the management of cholestatic liver diseases[J]. Clin Med (Lond), 2020, 20(5): 513-516. |
| [8] | Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver[J]. Mol Aspects Med, 2017, 56: 45-53. |
| [9] | Wu H, Chen C, Ziani S, et al. Fibrotic events in the progression of cholestatic liver disease[J]. Cells, 2021, 10(5): 1107. |
| [10] | 李飞, 陆伦根. 胆汁淤积和黄疸的诊断与鉴别诊断[J]. 内科理论与实践, 2018, 13(6): 385-387. |
| [11] | Šarenac TM, Mikov M. Bile acid synthesis: from nature to the chemical modification and synthesis and their applications as drugs and nutrients[J]. Front Pharmacol, 2018, 9: 939. |
| [12] | 宋丹军, 潘家琪, 李鹏旭, 等. 溶血磷脂酰胆碱在肝脏疾病中的研究进展[J]. 中国药理学通报, 2014, 12: 1642-1646. |
| [13] | Reichert MC, Hall RA, Krawczyk M, et al. Genetic determinants of cholangiopathies: molecular and systems genetics[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4): 1484-1490. |
| [14] | Karlsen TH, Lammert F, Thompson RJ. Genetics of liver disease: from pathophysiology to clinical practice[J]. J Hepatol, 2015, 62(1 Suppl): S6-S14. |
| [15] | García-Giménez JL, Seco-Cervera M, Tollefsbol TO, et al. Epigenetic biomarkers: current strategies and future challenges for their use in the clinical laboratory[J]. Crit Rev Clin Lab Sci, 2017, 54(7-8): 529-550. |
| [16] | van der Kolk JH, Pacholewska A, Gerber V. The role of microRNAs in equine medicine: a review[J]. Vet Q, 2015, 35(2): 88-96. |
| [17] | Kim YC, Jung H, Seok S, et al. MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice[J]. Hepatology, 2020, 71(6): 2118-2134. |
| [18] | Navaneethan U, Lourdusamy V, Gk Venkatesh P, et al. Bile proteomics for differentiation of malignant from benign biliary strictures[J]. Gastroenterol Rep (Oxf), 2015, 3(2): 136-143. |
/
| 〈 |
|
〉 |
